Israel Biotech Fund

About

Portfolio · 18

Vensica Medical

Needle-free Drug Delivery System for the Urinary Bladder

Led ★ 2 rounds $27.0M committed Latest: 2024-10

ProPhet

AI-driven Drug Discovery

1 round Latest: 2024-07

TenAces Biosciences

Molecular Glue Therapeutics

1 round Latest: 2024-01

MediWound

Enzymatic Therapeutics for Non-Surgical Tissue Repair

1 round $8.0M committed Latest: 2023-02

4C Biomed

Unlocking the Promise of Immune Checkpoint Inhibitors

Led ★ 1 round Latest: 2023-01

Nectin Therapeutics

Next-generation Immunotherapy Agents

Led ★ 1 round $13.6M committed Latest: 2022-12

AnserBio

Nanoparticle based delivery of p53 protein - addressing the most frequent mutation in cancer. -

Led ★ 2 rounds $1.0M committed Latest: 2021-12

Peles Therapeutics

Monoclonal Antibody Treatment for Peripheral Artery Disease

Led ★ 1 round Latest: 2021-07

SpliSense

Developing transformative RNA-based treatments for unmet needs relating to diverse pulmonary diseases.

1 round $28.5M committed Latest: 2021-05

MemoryPlus

Cognition Restoring Treatment for Alzheimer’s Disease

Led ★ 1 round Latest: 2021-01

Tamarix Pharma

Therapies for Apoptosis-driven Diseases

1 round Latest: 2021-01

BioSight

Therapeutics for Oncology and Hematological Disorders

Led ★ 2 rounds $46.0M committed Latest: 2020-12

Ayala Pharmaceuticals

Targeted Therapies for People with Rare Cancers

3 rounds $47.0M committed Latest: 2019-05

Biond Biologics

Immunotherapies for Cancer and Auto-immune Diseases

1 round $17.0M committed Latest: 2019-01

TPCera

Immunomodulatory Treatment for Autoimmune Diseases

1 round $3.0M committed Latest: 2018-07

Gamida Cell

Cellular and Immune Therapies

1 round $40.0M committed Latest: 2017-06

Pharma Two B

Innovative Combinations of Previously Approved Drugs

1 round $30.0M committed Latest: 2017-02

Vidac Pharma

Skin Cancer Treatment

1 round $9.0M committed Latest: 2016-06

Investment activity

4 portfolio exits on record.

Funds · 2

• 2 — $100M Apr 2021
• 1 — $66M Oct 2016

Q&A

What is Israel Biotech Fund's primary investment focus?

Israel Biotech Fund invests exclusively in Israeli and Israeli-related biotech companies across all development stages.

When was Israel Biotech Fund founded?

Israel Biotech Fund started its activity in late 2015.

What is the most recent fund raised by Israel Biotech Fund?

Israel Biotech Fund closed its second fund, Fund 2, in April 2021, raising $100M.

Can you name some of Israel Biotech Fund's notable exits?

Israel Biotech Fund has seen exits including BioSight, which was acquired by Ayala Pharmaceuticals in October 2023, and Vidac Pharma, which went public in March 2023.

Which investment stages does Israel Biotech Fund typically target?

Israel Biotech Fund invests across Pre-Seed, Seed, and A Round stages.

Who are some of the founding partners of Israel Biotech Fund?

The founding partners of Israel Biotech Fund include Yuval Cabilly, Ido Zairi, and David Sidransky.

What is Israel Biotech Fund's approach to supporting its portfolio companies?

Israel Biotech Fund provides its portfolio companies with hands-on guidance and necessary resources for long-term sustainable growth.

What is the sector concentration of Israel Biotech Fund's portfolio?

Israel Biotech Fund's portfolio is entirely concentrated in the Health Tech & Life Sciences sector, with 18 portfolio companies in this area.